Launch of Chronic Spontaneous Urticaria CME activity
A new CME activity on chronic spontaneous urticaria (CSU) has now launched on Medthority.com. ‘Case Consults: Changing Paradigms in the Age of Biologics’ has been accredited by the European Accreditation Council for Continuing Medical Education and is worth 1 CME credit on completion.
This activity is made up of three video presentations and two video case studies based on expert-led sessions from the Novartis-sponsored CSU symposium of the same name held at the 24th European Academy of Dermatology and Venereology (EADV) Congress 2015.
After watching these videos, participants will be asked 10 CME quiz questions and must achieve 70% or higher correct in order to pass the module. A downloadable PDF certificate is available on successful completion of this activity as proof of participation.
There is no fee for this CME activity
Related news and insights
Regeneron Pharmaceuticals, Inc., and Sanofi announced a Phase III trial (CUPID STUDY B) evaluating Dupixent (dupilumab) in patients with chronic spontaneous urticaria (CSU) will stop due to futility, based on a pre-specified interim analysis.